Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer
View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2019Author
Bilici, AhmetÖlmez, Ömer Fatih
Gürsoy, Pınar
Çubukçu, Erdem
Yıldız, Özcan
Sakın, Abdullah
Korkmaz, Taner
Çil, İbrahim
Çakar, Beyhan
Menekşe, Serkan
Demir, Tarık
Açıkgöz, Özgen
Hamdard, Jamshid
Metadata
Show full item recordCitation
Bilici, A., Ölmez, Ö. F., Gürsoy, P., Çubukçu, E., Yıldız, Ö., Sakın, A. ... Hamdard, J. (2019). Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology içinde (S664-S665. ss.). https://doi.org/10.1016/j.jtho.2019.08.1407Abstract
The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been also investigated in patients with both early and advanced non-small-cell lung cancer (NSCLC). However, determination of SIR predicting outcomes of patients who are likely to response to crizotinib in ALK-positive NSCLC patients has not been clearly demonstrated.
WoS Q Kategorisi
Q1Source
Journal of Thoracic OncologyVolume
14Issue
10Collections
- Bildiri Koleksiyonu [514]
- WoS İndeksli Yayınlar Koleksiyonu [6416]